

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 December 2022 (15.12.2022)



(10) International Publication Number
WO 2022/261341 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/7088 (2006.01)

(21) International Application Number:
PCT/US2022/032859

(22) International Filing Date:
09 June 2022 (09.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/209,075 10 June 2021 (10.06.2021) US

(71) Applicant: REGENERON PHARMACEUTICALS,
INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown,
New York 10591 (US).

(72) Inventors: HOROWITZ, Julie E.; 777 Old Saw Mill River
Road, Tarrytown, New York 10591 (US). FERREIRA,
Manuel Allen Revez; 777 Old Saw Mill River Road, Tarrytown,
New York 10591 (US). SIMINOVITCH, Katherine;
777 Old Saw Mill River Road, Tarrytown, New York
10591 (US). BARAS, Aris; 777 Old Saw Mill River Road,
Tarrytown, New York 10591 (US). KHRIMIAN, Lori;
777 Old Saw Mill River Road, Tarrytown, New York 10591
(US). KARALIS, Katia; 777 Old Saw Mill River Road,
Tarrytown, New York 10591 (US).

(74) Agent: LEGAARD, Paul K.; c/o Armstrong Teasdale
LLP, 7700 Forsyth Blvd., Suite 1800, St. Louis, Missouri
63105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TREATMENT OF PSORIASIS WITH INTERFERON INDUCED HELICASE C DOMAIN 1 (IFIH1) INHIBITORS

(57) Abstract: The present disclosure provides methods of treating subjects having psoriasis, and methods of identifying subjects having an increased risk of developing psoriasis.

WO 2022/261341 A1